Scientific

MK5 Microarray Data

Affected Genes - Ontology Breakdown - Gene Enrichment - Proteome Analysis

These are the micro-array results of a differential gene expression microarray experiments and the subsequent analysis steps performed on them. The up/down- regulation ratio was obtained by measuring WT cells against MK5 activated cells. See material and methods for technical information as well as the data usage policy.

MK5 Proteome Analysis

Table 3: Type II network, divided ranks. This table presents the output of the simulation of a type-II network in which we relied on the high confidence interactions and micro-array results. The output of the micro-array was then ranked and these ranks used as input into the network simulation. After performing two such simulations (one for the MK5 off and one for the MK5 on microarray output), we divided the ranks and sorted the results accordingly. The output of this technique is a collection of proteins that cluster naturally together.


Navigation/Query Panel:
Click on the attribute name to hide/unhide it. The green arrows can be used to shift columns left/right. Exact word match is written as =..., regular expressions can be matched with ~.... To select all values larger or equal than use >.... This would be <... for values smaller or equal than. To select all values within a specific range use [...,...].
Rank Gene Hugo description Value Type Network Comparison Type Interaction Map Filtered red green network_comparison
Results: HTML CSV LaTeX Showing element 1001 to 1050 of 3228 in total 
Value Type: Ranked
Network Comparison Type: Divided
Interaction Map: High confidence
Filtered: 1

\def\wcA{0.14285714285714\textwidth}
\def\wcB{0.14285714285714\textwidth}
\def\wcC{0.14285714285714\textwidth}
\def\wcD{0.14285714285714\textwidth}
\def\wcE{0.14285714285714\textwidth}
\def\wcF{0.14285714285714\textwidth}
\begin{longtable}{|c|c|c|c|c|c|}
\hline
\parbox{\wcA}{\vspace{3pt}\noindent
Rank\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
Hugo\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
description\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
red\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
green\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
network\_comparison\vspace{3pt}}\\
\hline
\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1001\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
SPRY3\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
sprouty homolog 3 (spry-3). [source:swissprot;acc:o43610]\vspace{3pt}}&\multirow{3}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
225.167\vspace{3pt}}}&\multirow{3}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
217.922\vspace{3pt}}}&\multirow{3}{*}{\parbox{\wcF}{\vspace{3pt}\noindent
1.03325\vspace{3pt}}}\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
1002\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
SPRY1\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
sprouty homolog 1 (spry-1) (fragment). [source:swissprot;acc:o43609]\vspace{3pt}}&&&\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
1003\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
SPRY2\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
sprouty homolog 2 (spry-2). [source:swissprot;acc:o43597]\vspace{3pt}}&&&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1004\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
sh2 domain binding protein 1; tpr-containing, sh2-binding phosphoprotein. [source:refseq;acc:nm\_014633]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
238.725\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
231.059\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.03318\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1005\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
DYNC1I1\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
dynein intermediate chain 1, cytosolic (dh ic-1) (cytoplasmic dynein intermediate chain 1). [source:swissprot;acc:o14576]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
225.448\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
218.232\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.03307\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1006\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
CPSF3\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
cleavage and polyadenylation specificity factor, 73 kda subunit (cpsf 73 kda subunit). [source:swissprot;acc:q9ukf6]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
116.524\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
120.375\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.03305\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1007\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
RALGDS\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
ral guanine nucleotide dissociation stimulator (ralgef) (ralgds). [source:swissprot;acc:q12967]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
162.055\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
156.884\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.03296\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1008\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
WDR46\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
wd-repeat protein bing4. [source:swissprot;acc:o15213]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
243.227\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
235.475\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.03292\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1009\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
dihydropyrimidine dehydrogenase [nadp+] precursor (ec 1.3.1.2) (dpd) (dhpdhase) (dihydrouracil dehydrogenase) (dihydrothymine dehydrogenase). [source:swissprot;acc:q12882]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
229.116\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
221.823\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.03288\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1010\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
CROT\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
peroxisomal carnitine octanoyltransferase (ec 2.3.1.-) (cot). [source:swissprot;acc:q9ukg9]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
217.523\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
210.648\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.03264\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1011\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
RBL2\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
retinoblastoma-like protein 2 (130 kda retinoblastoma-associated protein) (prb2) (p130) (rbr-2). [source:swissprot;acc:q08999]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
217.026\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
210.189\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.03253\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1012\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
RBL1\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
retinoblastoma-like protein 1 (107 kda retinoblastoma-associated protein) (prb1) (p107). [source:swissprot;acc:p28749]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
217.021\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
210.185\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.03252\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1013\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
HEATR1\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
protein bap28. [source:swissprot;acc:q9h583]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
244.312\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
236.647\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.03239\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1014\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
AATF\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
apoptosis antagonizing transcription factor. [source:refseq;acc:nm\_012138]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
243.045\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
235.422\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.03238\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1015\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
MAGI1\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
bai1-associated protein 1; ww domain-containing protein 3; atrophin-1 interacting protein 3. [source:refseq;acc:nm\_004742]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
221.73\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
228.906\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.03236\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1016\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
KPNA4\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
importin alpha-4 subunit (karyopherin alpha-4 subunit) (qip1 protein). [source:swissprot;acc:o00629]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
217.369\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
210.561\vspace{3pt}}&\multirow{3}{*}{\parbox{\wcF}{\vspace{3pt}\noindent
1.03233\vspace{3pt}}}\\\cline{1-5}
\parbox{\wcA}{\vspace{3pt}\noindent
1017\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
TOE1\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
target of egr1, member 1 (nuclear); target of egr1, member 1. [source:refseq;acc:nm\_025077]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
217.365\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
210.558\vspace{3pt}}&\\\cline{1-5}
\parbox{\wcA}{\vspace{3pt}\noindent
1018\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
KPNA3\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
importin alpha-3 subunit (karyopherin alpha-3 subunit) (srp1-gamma). [source:swissprot;acc:o00505]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
217.361\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
210.554\vspace{3pt}}&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1019\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
TYRL\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
tyrosinase-related gene segment, exon 5 (fragment). [source:sptrembl;acc:q15677]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
221.302\vspace{3pt}}&\multirow{3}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
214.409\vspace{3pt}}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.03215\vspace{3pt}}\\\cline{1-4}\cline{6-6}
\parbox{\wcA}{\vspace{3pt}\noindent
1020\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
DCT\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
dopachrome tautomerase precursor (ec 5.3.3.12) (dt) (dct) (dopachrome delta-isomerase) (tyrosinase-related protein 2) (trp-2) (trp2). [source:swissprot;acc:p40126]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
221.28\vspace{3pt}}&&\parbox{\wcF}{\vspace{3pt}\noindent
1.03205\vspace{3pt}}\\\cline{1-4}\cline{6-6}
\parbox{\wcA}{\vspace{3pt}\noindent
1021\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
TYRP1\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
5,6-dihydroxyindole-2-carboxylic acid oxidase precursor (ec 1.14.18.-) (dhica oxidase) (tyrosinase-related protein 1) (trp-1) (trp1) (trp) (catalase b) (glycoprotein-75) (melanoma antigen gp75). [source:swissprot;acc:p17643]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
221.278\vspace{3pt}}&&\parbox{\wcF}{\vspace{3pt}\noindent
1.03204\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1022\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
CBS\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
cystathionine beta-synthase (ec 4.2.1.22) (serine sulfhydrase) (beta-thionase). [source:swissprot;acc:p35520]\vspace{3pt}}&\multirow{5}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
205.632\vspace{3pt}}}&\multirow{5}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
199.266\vspace{3pt}}}&\multirow{5}{*}{\parbox{\wcF}{\vspace{3pt}\noindent
1.03195\vspace{3pt}}}\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
1023\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
RHOC\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
transforming protein rhoc (h9). [source:swissprot;acc:p08134]\vspace{3pt}}&&&\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
1024\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
TST\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
thiosulfate sulfurtransferase (ec 2.8.1.1) (rhodanese). [source:swissprot;acc:q16762]\vspace{3pt}}&&&\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
1025\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
MPST\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
3-mercaptopyruvate sulfurtransferase (ec 2.8.1.2) (mst). [source:swissprot;acc:p25325]\vspace{3pt}}&&&\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
1026\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
RHOA\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
transforming protein rhoa (h12). [source:swissprot;acc:p06749]\vspace{3pt}}&&&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1027\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
SUCLG1\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
succinyl-coa ligase [gdp-forming] alpha-chain, mitochondrial precursor (ec 6.2.1.4) (succinyl-coa synthetase, alpha chain) (scs-alpha). [source:swissprot;acc:p53597]\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
211.908\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
218.627\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcF}{\vspace{3pt}\noindent
1.03171\vspace{3pt}}}\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
1028\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
SUCLA2\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
succinyl-coa ligase [adp-forming] beta-chain, mitochondrial precursor (ec 6.2.1.5) (succinyl-coa synthetase, betaa chain) (scs-betaa) (atp- specific succinyl-coa synthetase beta subunit). [source:swissprot;acc:q9p2r7]\vspace{3pt}}&&&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1029\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
DDB1\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
dna damage binding protein 1 (damage-specific dna binding protein 1) (ddb p127 subunit) (ddba) (uv-damaged dna-binding protein 1) (uv-ddb 1) (xeroderma pigmentosum group e complementing protein) (xpce) (x- associated protein 1) (xap-1). [source:swissprot;acc:q16531]\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
222.364\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
215.535\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcF}{\vspace{3pt}\noindent
1.03168\vspace{3pt}}}\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
1030\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
PCCB\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
propionyl-coa carboxylase beta chain, mitochondrial precursor (ec 6.4.1.3) (pccase beta subunit) (propanoyl-coa:carbon dioxide ligase beta subunit). [source:swissprot;acc:p05166]\vspace{3pt}}&&&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1031\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
EMG1\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
probable ribosome biogenesis protein nep1 (c2f protein). [source:swissprot;acc:q92979]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
242.978\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
235.518\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.03167\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1032\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
AGPAT2\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
1-acyl-sn-glycerol-3-phosphate acyltransferase beta (ec 2.3.1.51) (1- agp acyltransferase 2) (1-agpat 2) (lysophosphatidic acid acyltransferase-beta) (lpaat-beta) (1-acylglycerol-3-phosphate o- acyltransferase 2). [source:swissprot;acc:o15120]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
186.664\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
180.943\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.03162\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1033\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
TYR\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
tyrosinase precursor (ec 1.14.18.1) (monophenol monooxygenase) (tumor rejection antigen ab) (sk29-ab) (lb24-ab). [source:swissprot;acc:p14679]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
221.183\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
214.406\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.03161\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1034\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
ESRRB\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
steroid hormone receptor err2 (estrogen-related receptor, beta) (err-beta) (estrogen receptor-like 2) (err beta-2). [source:swissprot;acc:o95718]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
186.551\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
180.837\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.0316\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1035\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
MAGI2\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
atrophin-1 interacting protein 1; activin receptor interacting protein 1; likely ortholog of mouse activin receptor interacting protein 1; atrophin-1 interacting protein a; membrane associated guanylate kinase 2; activin receptor interacting p. [source:refseq;acc:nm\_012301]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
221.682\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
228.68\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.03157\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1036\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
COPB1\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
coatomer beta subunit (beta-coat protein) (beta-cop). [source:swissprot;acc:p53618]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
171.341\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
176.746\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.03155\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1037\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
GLRX3\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
thioredoxin-like; pkc-interacting cousin of thioredoxin. [source:refseq;acc:nm\_006541]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
228.412\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
235.609\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.03151\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1038\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
1-acyl-sn-glycerol-3-phosphate acyltransferase alpha (ec 2.3.1.51) (1- agp acyltransferase 1) (1-agpat 1) (lysophosphatidic acid acyltransferase-alpha) (lpaat-alpha) (1-acylglycerol-3-phosphate o- acyltransferase 1) (g15 protein). [source:swissprot;acc:q99943]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
186.741\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
181.041\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.03148\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1039\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
DLD\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
dihydrolipoamide dehydrogenase, mitochondrial precursor (ec 1.8.1.4) (glycine cleavage system l protein). [source:swissprot;acc:p09622]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
207.719\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
214.236\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.03137\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1040\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
CCT5\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
t-complex protein 1, epsilon subunit (tcp-1-epsilon) (cct-epsilon). [source:swissprot;acc:p48643]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
163.24\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
168.359\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.03136\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1041\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
HNRNPL\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
heterogeneous nuclear ribonucleoprotein l (hnrnp l). [source:swissprot;acc:p14866]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
186.774\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
181.099\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.03134\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1042\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
estrogen-related receptor gamma (estrogen receptor related protein 3) (err gamma-2). [source:swissprot;acc:o75454]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
186.799\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
181.127\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.03132\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1043\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
AGPAT3\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
1-acyl-sn-glycerol-3-phosphate acyltransferase gamma (ec 2.3.1.51) (1- agp acyltransferase 3) (1-agpat 3) (lysophosphatidic acid acyltransferase-gamma) (lpaat-gamma) (1-acylglycerol-3-phosphate o- acyltransferase 3). [source:swissprot;acc:q9nrz7]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
187.834\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
182.137\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.03128\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1044\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
DYNLT3\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
t-complex associated-testis-expressed 1-like (protein 91/23). [source:swissprot;acc:p51808]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
173.475\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
178.889\vspace{3pt}}&\multirow{3}{*}{\parbox{\wcF}{\vspace{3pt}\noindent
1.03121\vspace{3pt}}}\\\cline{1-5}
\parbox{\wcA}{\vspace{3pt}\noindent
1045\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
FIP1L1\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
fip1-like 1; rearranged in hypereosinophilia. [source:refseq;acc:nm\_030917]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
115.817\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
119.432\vspace{3pt}}&\\\cline{1-5}
\parbox{\wcA}{\vspace{3pt}\noindent
1046\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
MRE11A\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
double-strand break repair protein mre11a (mre11 homolog 1). [source:swissprot;acc:p49959]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
173.475\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
178.889\vspace{3pt}}&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1047\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
ESRRA\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
steroid hormone receptor err1 (estrogen-related receptor, alpha) (err-alpha) (estrogen receptor-like 1). [source:swissprot;acc:p11474]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
187.022\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
181.391\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.03104\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1048\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
AGPAT4\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
1-acyl-sn-glycerol-3-phosphate acyltransferase delta (ec 2.3.1.51) (1- agp acyltransferase 4) (1-agpat 4) (lysophosphatidic acid acyltransferase-delta) (lpaat-delta) (1-acylglycerol-3-phosphate o- acyltransferase 4). [source:swissprot;acc:q9nrz5]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
187.96\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
182.308\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.031\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1049\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
adenine phosphoribosyltransferase (ec 2.4.2.7) (aprt). [source:swissprot;acc:p07741]\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
211.449\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
217.998\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcF}{\vspace{3pt}\noindent
1.03097\vspace{3pt}}}\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
1050\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
HSD17B1\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
estradiol 17 beta-dehydrogenase 1 (ec 1.1.1.62) (17-beta-hsd 1) (placental 17-beta-hydroxysteroid dehydrogenase) (20 alpha- hydroxysteroid dehydrogenase) (20-alpha-hsd) (e2dh). [source:swissprot;acc:p14061]\vspace{3pt}}&&&\\\hline
nd{longtable}

Legend:
- Rank is the rank after comparing the two networks

 - Gene is the ensembl human gene identifier measured by 1 or more probes on the microarray

 - Hugo is the HGNC identifier if it exists

 - Value Type describes how the microarray measurement was processed. Ranked indicates that we sorted all measurements and use the rank as red and green value. Measured is the normal measurement. Squared and Rooted are the square and square root respecitcely. This might be valueable to compensate for non linear light distributions.

 - Network Comparison Type describes whether we divided the red and green types or whether we sutractcted them

 - Interaction Map specifies whether we used only the hig hconfidence protein-protein interactions or also included the low confidence interactions.

 - Filtered specifies whether we only included the high confidence microarry measurements or not.
- http://analysis.yellowcouch.org/